Inozyme Pharma Statistics
Total Valuation
Inozyme Pharma has a market cap or net worth of $259.66 million. The enterprise value is $221.84 million.
| Market Cap | 259.66M |
| Enterprise Value | 221.84M |
Important Dates
The last earnings date was Wednesday, August 6, 2025, before market open.
| Earnings Date | Aug 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Inozyme Pharma has 64.92 million shares outstanding. The number of shares has increased by 12.58% in one year.
| Current Share Class | 64.92M |
| Shares Outstanding | 64.92M |
| Shares Change (YoY) | +12.58% |
| Shares Change (QoQ) | +0.05% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.35% |
| Float | 64.92M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 8.17 |
| P/TBV Ratio | 8.17 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.08 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -2.30 |
Financial Position
The company has a current ratio of 2.19, with a Debt / Equity ratio of 1.48.
| Current Ratio | 2.19 |
| Quick Ratio | 1.98 |
| Debt / Equity | 1.48 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.49 |
| Interest Coverage | -18.70 |
Financial Efficiency
Return on equity (ROE) is -141.69% and return on invested capital (ROIC) is -53.98%.
| Return on Equity (ROE) | -141.69% |
| Return on Assets (ROA) | -48.45% |
| Return on Invested Capital (ROIC) | -53.98% |
| Return on Capital Employed (ROCE) | -201.35% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.59M |
| Employee Count | 67 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -10.31% in the last 52 weeks. The beta is 2.26, so Inozyme Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 2.26 |
| 52-Week Price Change | -10.31% |
| 50-Day Moving Average | 2.85 |
| 200-Day Moving Average | 2.79 |
| Relative Strength Index (RSI) | 82.70 |
| Average Volume (20 Days) | 1,079,382 |
Short Selling Information
The latest short interest is 3.38 million, so 5.21% of the outstanding shares have been sold short.
| Short Interest | 3.38M |
| Short Previous Month | 3.68M |
| Short % of Shares Out | 5.21% |
| Short % of Float | 11.23% |
| Short Ratio (days to cover) | 1.34 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -105.47M |
| Pretax Income | -106.72M |
| Net Income | -106.72M |
| EBITDA | -104.74M |
| EBIT | -105.47M |
| Earnings Per Share (EPS) | -$1.68 |
Balance Sheet
The company has $84.78 million in cash and $46.95 million in debt, giving a net cash position of $37.82 million or $0.58 per share.
| Cash & Cash Equivalents | 84.78M |
| Total Debt | 46.95M |
| Net Cash | 37.82M |
| Net Cash Per Share | $0.58 |
| Equity (Book Value) | 31.80M |
| Book Value Per Share | 0.49 |
| Working Capital | 50.86M |
Cash Flow
In the last 12 months, operating cash flow was -$96.52 million and capital expenditures -$30,000, giving a free cash flow of -$96.55 million.
| Operating Cash Flow | -96.52M |
| Capital Expenditures | -30,000 |
| Free Cash Flow | -96.55M |
| FCF Per Share | -$1.49 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Inozyme Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.58% |
| Shareholder Yield | n/a |
| Earnings Yield | -41.10% |
| FCF Yield | -37.18% |
Analyst Forecast
The average price target for Inozyme Pharma is $15.22, which is 280.50% higher than the current price. The consensus rating is "Buy".
| Price Target | $15.22 |
| Price Target Difference | 280.50% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |